Voloridge Investment Management
VRDN icon

Voloridge Investment Management’s Viridian Therapeutics VRDN Stock Holding History

Voloridge Investment Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,119
Closed -$207K – 1590
2023
Q1 		$207K Buy
+8,119
New +$260K ﹤0.01% 1310

Other funds holding VRDN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Voloridge Investment Management's VRDN Position: Q2 2023 in Review

Voloridge Investment Management sold out of Viridian Therapeutics (VRDN) in Q2 2023, closing a stake of 8,119 shares — an estimated $207K sold.

Voloridge Investment Management first reported a position in VRDN in Q1 2023 and held it in 1 quarter. The position peaked at $207K in Q1 2023. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.

  • Voloridge Investment Management reported no remaining Viridian Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Voloridge Investment Management sold 8,119 Viridian Therapeutics shares in Q2 2023, an estimated $207K.
  • Voloridge Investment Management first reported a position in Viridian Therapeutics in Q1 2023 and held it in 1 quarter.
  • Voloridge Investment Management's Viridian Therapeutics position peaked at $207K in Q1 2023.
  • 128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.

Based on Voloridge Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.